MCID: FBR017
MIFTS: 55

Fibrosarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Fibrosarcoma

MalaCards integrated aliases for Fibrosarcoma:

Name: Fibrosarcoma 11 19 58 75 28 53 43 14 16 71
Neoplasms, Fibrous Tissue 43 71
Fibrosarcoma of Soft Tissue 11
Fibrous Tissue Neoplasm 11
Fibrocytic Tumor 11

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 11 DOID:3355
SNOMED-CT 68 443250000
MESH via Orphanet 44 D005354
ICD10 via Orphanet 32 C49.9
UMLS via Orphanet 72 C0016057
Orphanet 58 ORPHA2030
UMLS 71 C0016057 C0206643 C1336021

Summaries for Fibrosarcoma

Disease Ontology: 11 A connective tissue cancer that has material basis in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern.

MalaCards based summary: Fibrosarcoma, also known as neoplasms, fibrous tissue, is related to adult fibrosarcoma and kidney fibrosarcoma. An important gene associated with Fibrosarcoma is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Response to elevated platelet cytosolic Ca2+. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, endothelial and bone marrow, and related phenotypes are shRNA abundance <= 50% and Reduced mammosphere formation

GARD: 19 A fibroblastic sarcoma is a malignant tumor derived from fibrous connective tissue and characterized by immature proliferating fibroblasts or undifferentiated anaplastic spindle cells.

Wikipedia: 75 Fibrosarcoma (fibroblastic sarcoma) is a malignant mesenchymal tumour derived from fibrous connective... more...

Related Diseases for Fibrosarcoma

Diseases in the Fibrosarcoma family:

Adult Fibrosarcoma Congenital Fibrosarcoma

Diseases related to Fibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 620)
# Related Disease Score Top Affiliating Genes
1 adult fibrosarcoma 32.5 NTRK3 ETV6
2 kidney fibrosarcoma 32.4 NTRK3 ETV6
3 fibroma 32.0 VIM MALAT1 FN1
4 nephroma 31.2 VIM NTRK3 ETV6
5 spindle cell sarcoma 31.1 VIM NTRK3 ETV6
6 fasciitis 31.0 VIM TNF ETV6
7 osteogenic sarcoma 30.9 MMP9 MMP2 MALAT1 JUN
8 aortic aneurysm 30.9 TNF TIMP2 TIMP1 SERPINE1 MMP9 MMP2
9 cellular congenital mesoblastic nephroma 30.8 NTRK3 ETV6
10 breast adenocarcinoma 30.7 TNF NTRK3 MMP9 MMP2 JUN FN1
11 vascular disease 30.6 TNF TIMP2 TIMP1 SERPINE1 MMP9 MMP2
12 aortic aneurysm, familial abdominal, 1 30.6 TNF TIMP2 TIMP1 SERPINE1 PLAU MMP9
13 disseminated intravascular coagulation 30.5 TNF SERPINE1 FN1
14 pneumothorax 30.5 VIM TIMP2 TIMP1 MMP9 MMP2
15 breast secretory carcinoma 30.4 NTRK3 ETV6
16 breast cancer 30.4 VIM TNF TIMP2 TIMP1 SERPINE1 PLAU
17 arthropathy 30.3 TNF TIMP1 MMP2
18 periodontitis 30.3 TNF TIMP1 MMP9 MMP2
19 hyperglycemia 30.3 TNF SERPINE1 MALAT1 JUN
20 corneal ulcer 30.3 TNF MMP9 MMP2 FN1
21 anaplastic astrocytoma 30.3 TIMP2 PLAU MMP9 MMP2
22 retinal detachment 30.3 VIM TNF TIMP1 MMP9 MMP2
23 urinary tract obstruction 30.2 TNF SERPINE1 FN1
24 varicose veins 30.2 TNF TIMP2 TIMP1 MMP9 MMP2 FN1
25 melanoma 30.2 VIM TNF TIMP2 TIMP1 PLAU MMP9
26 connective tissue disease 30.1 TNF TIMP1 MMP9 MMP2 JUN FN1
27 aortic aneurysm, familial thoracic 1 30.1 TNF TIMP2 TIMP1 SERPINE1 MMP9 MMP2
28 epithelial-myoepithelial carcinoma 30.1 NTRK3 ETV6
29 monocytic leukemia 30.1 TNF MMP9 JUN
30 renal cell carcinoma, nonpapillary 30.1 VIM TNF TIMP2 MMP9 MMP2 MALAT1
31 glioma 30.1 TIMP2 PLAU NTRK3 MMP9 MMP2 MALAT1
32 neuroblastoma 30.0 TNF NTRK3 MMP9 MMP2 MALAT1 JUN
33 liver cirrhosis 30.0 TNF TIMP2 TIMP1 MALAT1
34 leukemia, acute myeloid 30.0 TNF MMP9 MALAT1 JUN FN1 ETV6
35 bladder cancer 30.0 TNF TIMP2 PLAU MMP9 MMP2 MMP14
36 adenocarcinoma 29.9 TIMP2 TIMP1 MMP9 MMP2 MALAT1
37 high grade glioma 29.9 TIMP2 MMP9 MMP2 MMP14 MALAT1
38 lung cancer susceptibility 3 29.8 PLAU MMP9 MMP2 MALAT1 JUN
39 rheumatoid arthritis 29.8 TNF TIMP2 TIMP1 MMP9 MMP2 MMP14
40 pancreatic cancer 29.7 VIM TNF TIMP1 PLAU MMP9 MMP2
41 gastric cancer 29.7 TNF TIMP2 TIMP1 PLAU MMP9 MMP2
42 ovarian cancer 29.7 VIM TNF TIMP2 TIMP1 SERPINE1 PLAU
43 prostate cancer 29.7 VIM TNF TIMP2 TIMP1 SERPINE1 PLAU
44 congenital fibrosarcoma 11.4
45 small bowel fibrosarcoma 11.4
46 heart fibrosarcoma 11.3
47 liver fibrosarcoma 11.3
48 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
49 breast fibrosarcoma 11.3
50 childhood fibrosarcoma 11.2

Graphical network of the top 20 diseases related to Fibrosarcoma:



Diseases related to Fibrosarcoma

Symptoms & Phenotypes for Fibrosarcoma

GenomeRNAi Phenotypes related to Fibrosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.43 JUN MAFB MMP14 MMP2 SERPINE1 TIMP2
2 Reduced mammosphere formation GR00396-S 9.17 ETV6 JUN MMP14 MMP2 TIMP1 TIMP2

MGI Mouse Phenotypes related to Fibrosarcoma:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.45 FN1 JUN MAF MAFB MAFG MAFK
2 homeostasis/metabolism MP:0005376 10.45 ETV6 FN1 JUN MAF MAFA MAFB
3 growth/size/body region MP:0005378 10.44 ETV6 FN1 JUN MAF MAFA MAFB
4 normal MP:0002873 10.37 ETV6 FN1 JUN MAFA MAFB MAFF
5 immune system MP:0005387 10.36 ETV6 FN1 JUN MAF MAFB MAFG
6 cardiovascular system MP:0005385 10.35 ETV6 FN1 JUN MAF MAFB MMP14
7 cellular MP:0005384 10.27 ETV6 FN1 JUN MAFB MAFG MAFK
8 behavior/neurological MP:0005386 10.27 JUN MAF MAFB MAFG MAFK MMP14
9 muscle MP:0005369 10.26 FN1 MAFG MAFK MMP14 MMP2 MMP9
10 renal/urinary system MP:0005367 10.22 ETV6 MAF MAFA MAFB MMP14 MMP2
11 endocrine/exocrine gland MP:0005379 10.22 ETV6 JUN MAF MAFA MAFB MMP14
12 neoplasm MP:0002006 10.2 ETV6 FN1 MMP2 MMP9 PLAU SERPINE1
13 reproductive system MP:0005389 10.15 FN1 MAF MAFB MAFK MMP14 MMP2
14 respiratory system MP:0005388 10.14 JUN MAFB MMP14 MMP2 MMP9 NTRK3
15 no phenotypic analysis MP:0003012 10.13 ETV6 JUN MAFA MALAT1 MMP14 NTRK3
16 craniofacial MP:0005382 10.11 FN1 JUN MAF MAFB MMP14 MMP2
17 skeleton MP:0005390 10.06 ETV6 FN1 JUN MAFB MMP14 MMP2
18 hematopoietic system MP:0005397 10.03 ETV6 FN1 JUN MAF MAFG MAFK
19 vision/eye MP:0005391 9.96 JUN MAF MMP14 MMP2 MMP9 NTRK3
20 mortality/aging MP:0010768 9.86 ETV6 FN1 JUN MAF MAFB MAFG
21 integument MP:0010771 9.32 ETV6 FN1 JUN MAF MMP14 MMP2

Drugs & Therapeutics for Fibrosarcoma

Drugs for Fibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
7
Methylprednisolone Acetate Phase 4 584547
8
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
9
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
10 Liposomal doxorubicin Phase 2, Phase 3
11
Idarubicin Approved Phase 1, Phase 2 58957-92-9 42890
12
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239
13
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
14
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
15
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
16
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
20
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
21
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
22
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
23
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
24
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
25
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
26
Dacarbazine Approved, Investigational Phase 2 4342-03-4 2942 5351166
27
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
28
Topotecan Approved, Investigational Phase 1, Phase 2 123948-87-8, 119413-54-6 60699 60700
29
Ifosfamide Approved Phase 2 3778-73-2 3690
30
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
31
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
32
Etoposide Approved Phase 2 33419-42-0 36462
33
Lenograstim Approved, Investigational Phase 2 135968-09-1
34
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
35
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
36
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
37
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 1, Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
38
Saracatinib Investigational Phase 2 379231-04-6 10302451
39
Palifosfamide Investigational Phase 2 31645-39-3 100427
40 Immunoglobulins Phase 2
41 Antibodies, Monoclonal Phase 2
42 Antibodies Phase 2
43 Antiviral Agents Phase 1, Phase 2
44 Endothelial Growth Factors Phase 1, Phase 2
45 Albumin-Bound Paclitaxel Phase 1, Phase 2
46 Taxane Phase 1, Phase 2 108169
47 Angiogenesis Inhibitors Phase 2
48
Imatinib Mesylate Phase 2 220127-57-1
49 Antineoplastic Agents, Immunological Phase 2
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial Not yet recruiting NCT05440240 Phase 4 Corticosteroid injection
2 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
4 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
5 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML Completed NCT00542971 Phase 1, Phase 2 Idarubicin;Sorafenib;Ara-C
6 A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. Completed NCT01962103 Phase 1, Phase 2 nab-paclitaxel
7 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
8 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
9 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
10 A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans Completed NCT00084630 Phase 2 imatinib mesylate
11 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
12 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
13 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
14 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
15 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
16 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Completed NCT01532687 Phase 2 Gemcitabine;Gemcitabine Hydrochloride;Pazopanib;Pazopanib Hydrochloride
17 Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor Completed NCT02261207 Phase 2 Axitinib
18 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
19 ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING) Recruiting NCT03840772 Phase 2 Eribulin
20 Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients Recruiting NCT03023124 Phase 2 Trabectedin;Adriamycin;Dacarbazine
21 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
22 Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Active, not recruiting NCT03834961 Phase 2 Larotrectinib Sulfate
23 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
24 A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) Active, not recruiting NCT02066285 Phase 2 Pazopanib
25 A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Enrolling by invitation NCT05266196 Phase 1, Phase 2 Seclidemstat
26 A Pilot Phase II Study for Children With Infantile Fibrosarcoma Terminated NCT00072280 Phase 2 cyclophosphamide;etoposide;ifosfamide;vincristine sulfate
27 S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors Terminated NCT00003292 Phase 2 ifosfamide
28 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
29 Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas Recruiting NCT03600649 Phase 1 Seclidemstat;Cyclophosphamide;Topotecan
30 A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas Active, not recruiting NCT03009201 Phase 1 Doxorubicin Hydrochloride;Ribociclib
31 A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma Active, not recruiting NCT04420975 Phase 1
32 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
33 Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. A Multicenter Study. Unknown status NCT01694654
34 A Comparison of Clinical Outcomes in Infantile Fibrosarcoma (IFS) Patients Treated With Larotrectinib in the Phase I/II SCOUT Study Versus (an) External Historical Cohort(s) Completed NCT05236257 Larotrectinib (Vitrakvi, BAY2757556);Standard of Care
35 Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) Completed NCT01567046
36 Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Recruiting NCT03967834
37 Staging Procedures to Diagnose Malignant Pleural Mesothelioma Recruiting NCT02648763
38 Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma Recruiting NCT02613312
39 Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma Recruiting NCT02613299
40 Rechallenge of Rapidly Accelerated Fibrosarcoma B-type (BRAF) +/- Mitogen-activated Extracellular Signal-regulated Kinase (MEK) Inhibitors Following an Adverse Event in Patients With Cancer Active, not recruiting NCT05080361 BRAF inhibitor
41 Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) Not yet recruiting NCT05515068
42 Orbital Solitary Fibrous Tumors: Description of a Case Series and Study of the Recurrence Rate Not yet recruiting NCT05613244

Search NIH Clinical Center for Fibrosarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dacarbazine

Cochrane evidence based reviews: fibrosarcoma

Genetic Tests for Fibrosarcoma

Genetic tests related to Fibrosarcoma:

# Genetic test Affiliating Genes
1 Fibrosarcoma 28

Anatomical Context for Fibrosarcoma

Organs/tissues related to Fibrosarcoma:

MalaCards : Bone, Endothelial, Bone Marrow, Lung, T Cells, Breast, Liver

Publications for Fibrosarcoma

Articles related to Fibrosarcoma:

(show top 50) (show all 10247)
# Title Authors PMID Year
1
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. 53 62
20406839 2010
2
Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. 53 62
20408816 2010
3
Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. 53 62
20442303 2010
4
The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. 53 62
19913614 2010
5
The benzoylurea derivative F13 inhibits cell growth, migration and invasion through inducing expression of ERK1/2-mediated RECK in fibrosarcoma HT-1080 cells. 53 62
20051826 2010
6
The role of MT2-MMP in cancer progression. 53 62
20117087 2010
7
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. 53 62
19551841 2010
8
Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. 53 62
19862822 2010
9
Inhibition of the expression on MMP-2, 9 and morphological changes via human fibrosarcoma cell line by 6,6'-bieckol from marine alga Ecklonia cava. 53 62
20132738 2010
10
Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. 53 62
19846557 2009
11
Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression. 53 62
19961596 2009
12
Insulin but not glucagon gene is silenced in human pancreas-derived mesenchymal stem cells. 53 62
19785038 2009
13
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 53 62
19910495 2009
14
bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells. 53 62
19577615 2009
15
Stabilization of anaphase midzone microtubules is regulated by Rho during cytokinesis in human fibrosarcoma cells. 53 62
19576212 2009
16
[Mechanism of endothelial Rho/Rho kinase in extravascular migration of fibrosarcoma cell]. 53 62
19968078 2009
17
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. 53 62
19342157 2009
18
Identification of integrins alpha6 and beta7 as c-Jun- and transformation-relevant genes in highly invasive fibrosarcoma cells. 53 62
19405119 2009
19
Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. 53 62
19571375 2009
20
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. 53 62
19478560 2009
21
Autotaxin promotes the expression of matrix metalloproteinase-3 via activation of the MAPK cascade in human fibrosarcoma HT-1080 cells. 53 62
19212832 2009
22
A novel mode of cell detachment from fibrillar fibronectin matrix under shear. 53 62
19401337 2009
23
The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. 53 62
19375915 2009
24
LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. 53 62
19366727 2009
25
Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. 53 62
19234490 2009
26
[Triptolide evaluates DNA methylation level of matrix metalloproteinase 9 gene in human fibrosarcoma HT-1080 cells]. 53 62
19526795 2009
27
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA. 53 62
18495463 2009
28
Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. 53 62
19368127 2009
29
Mapping proteolytic cancer cell-extracellular matrix interfaces. 53 62
18600304 2009
30
TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. 53 62
19077262 2008
31
Use of the Rad51 promoter for targeted anti-cancer therapy. 53 62
19106292 2008
32
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. 53 62
18802920 2008
33
Transcription factors as therapeutic targets for diabetes. 53 62
18851698 2008
34
Mapping local matrix remodeling induced by a migrating tumor cell using three-dimensional multiple-particle tracking. 53 62
18641063 2008
35
Glucose regulation of insulin gene expression in pancreatic beta-cells. 53 62
18778246 2008
36
Flavonoid glycosides isolated from Salicornia herbacea inhibit matrix metalloproteinase in HT1080 cells. 53 62
18715546 2008
37
Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. 53 62
18681831 2008
38
Wdnm1-like, a new adipokine with a role in MMP-2 activation. 53 62
18492766 2008
39
Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. 53 62
18421307 2008
40
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. 53 62
18627313 2008
41
Efrapeptin J, a new down-regulator of the molecular chaperone GRP78 from a marine Tolypocladium sp. 53 62
18667784 2008
42
Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. 53 62
18413233 2008
43
Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. 53 62
18454665 2008
44
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. 53 62
18451175 2008
45
Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. 53 62
18401718 2008
46
Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. 53 62
18483249 2008
47
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. 53 62
18392131 2008
48
Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock. 53 62
18283592 2008
49
Collagen-binding domains of gelatinase A and thrombospondin-derived peptides impede endocytic clearance of active gelatinase A and promote HT1080 fibrosarcoma cell invasion. 53 62
18222489 2008
50
Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. 53 62
17980161 2008

Variations for Fibrosarcoma

Expression for Fibrosarcoma

Search GEO for disease gene expression data for Fibrosarcoma.

Pathways for Fibrosarcoma

Pathways related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 VIM TNF TIMP1 MMP9 MMP2 JUN
2
Show member pathways
13.24 FN1 MAFF MAFG MAFK PLAU SERPINE1
3
Show member pathways
12.7 FN1 MMP14 MMP2 MMP9 SERPINE1 TIMP1
4 12.68 PLAU MMP9 MMP2 MMP14 JUN FN1
5 12.14 TNF MMP9 MMP2 MMP14
6 12 SERPINE1 MMP9 MMP2 MMP14
7 11.92 VIM TNF MMP9
8
Show member pathways
11.91 TNF SERPINE1 JUN
9 11.9 SERPINE1 PLAU MMP14 JUN FN1
10 11.85 MMP2 MMP9 TIMP1 TIMP2
11 11.83 VIM TNF TIMP1 MMP9 MMP2 FN1
12 11.81 VIM TIMP2 TIMP1 MMP2 FN1
13 11.76 TNF TIMP1 MMP9 MMP2
14
Show member pathways
11.73 TNF TIMP2 TIMP1 MMP9 MMP2 MMP14
15 11.69 MMP9 MMP2 JUN
16
Show member pathways
11.67 TNF MMP9 MMP2 JUN
17
Show member pathways
11.66 TNF MAF JUN
18
Show member pathways
11.65 MMP9 MMP2 JUN
19
Show member pathways
11.59 TNF MAF JUN
20 11.57 PLAU MMP2 JUN
21 11.57 TNF TIMP1 PLAU MMP9 MMP2
22 11.54 PLAU MMP9 JUN
23 11.47 MMP9 MMP2 JUN
24 11.47 TIMP1 PLAU MMP9 MAFG MAF JUN
25 11.42 SERPINE1 PLAU MMP9 FN1
26 11.34 PLAU MMP9 MMP2 JUN
27 11.25 PLAU MMP9 MMP2 JUN
28 11.17 MMP2 MMP9 PLAU TNF
29 11.16 TIMP2 TIMP1 MMP9
30 11.14 MAFK MAFG MAFF MAFB MAFA MAF
31 11.01 TIMP2 TIMP1 SERPINE1 PLAU MMP9 MMP2
32 10.99 VIM TNF TIMP2 TIMP1 NTRK3 JUN
33 10.93 MAFK MAFG JUN
34 10.9 PLAU FN1
35 10.85 FN1 TIMP1 VIM
36 10.82 VIM FN1
37 10.78 PLAU MMP9
38 10.78 SERPINE1 PLAU
39 10.67 MAFK MAFG MAFF

GO Terms for Fibrosarcoma

Cellular components related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.65 TIMP2 TIMP1 MMP9 MMP2 MMP14 FN1
2 serine protease inhibitor complex GO:0097180 9.46 SERPINE1 PLAU
3 RNA polymerase II transcription regulator complex GO:0090575 9.36 MAFK MAFG MAFF MAFB MAF JUN

Biological processes related to Fibrosarcoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.34 TNF MAFK MAFG MAFF MAFB MAF
2 positive regulation of gene expression GO:0010628 10.28 VIM TNF NTRK3 MAFG MAF FN1
3 response to hypoxia GO:0001666 10.2 TNF PLAU MMP2 MMP14
4 regulation of DNA-templated transcription GO:0006355 10.19 MAFK MAFG MAFF MAFB MAFA MAF
5 angiogenesis GO:0001525 10.1 SERPINE1 MMP2 MMP14 JUN FN1
6 ephrin receptor signaling pathway GO:0048013 10.04 NTRK3 MMP9 MMP2
7 response to mechanical stimulus GO:0009612 10 TNF MMP2 MMP14
8 extracellular matrix disassembly GO:0022617 9.99 MMP9 MMP2 MMP14
9 response to organic substance GO:0010033 9.97 TNF TIMP2 TIMP1
10 response to cytokine GO:0034097 9.96 TIMP2 TIMP1 MMP2
11 response to hormone GO:0009725 9.95 MMP14 TIMP1 TIMP2
12 collagen catabolic process GO:0030574 9.95 MMP14 MMP2 MMP9
13 cellular response to reactive oxygen species GO:0034614 9.93 MMP9 MMP2 JUN
14 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.89 TIMP2 TIMP1
15 negative regulation of plasminogen activation GO:0010757 9.88 SERPINE1 PLAU
16 negative regulation of vascular wound healing GO:0061044 9.83 TNF SERPINE1
17 integrated stress response signaling GO:0140467 9.73 MAFB MAF JUN
18 regulation of epidermal cell differentiation GO:0045604 9.67 MAFF MAFG
19 cellular response to UV-A GO:0071492 9.63 TIMP1 MMP9 MMP2
20 negative regulation of metallopeptidase activity GO:1905049 9.62 TIMP1 TIMP2
21 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.56 TNF MMP9 MMP2 JUN
22 endodermal cell differentiation GO:0035987 9.23 MMP9 MMP2 MMP14 FN1

Molecular functions related to Fibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific double-stranded DNA binding GO:1990837 10.03 MAFG MAFF MAFB MAFA MAF JUN
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 10 ETV6 JUN MAF MAFA MAFB MAFF
3 DNA-binding transcription factor activity GO:0003700 9.77 MAFK MAFG MAFF MAFB MAFA MAF
4 protease binding GO:0002020 9.32 TNF TIMP2 TIMP1 SERPINE1 FN1

Sources for Fibrosarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....